Treatment of infant formula with patiromer dose dependently decreases potassium concentration
Hyperkalemia is a potentially life-threatening complication of chronic kidney disease (CKD). Dietary potassium restriction is challenging in infants despite low-potassium formulas. Decreasing potassium in formula using patiromer, a new calcium-based cation exchange polymer may be one option to accomplish this; however, data confirming efficacy is lacking.
Varying doses of patiromer were added to prepared Similac Advance and Similac PM 60/40. Measurements of potassium, calcium, sodium, magnesium, and phosphorus were obtained at baseline and at 30 min, 60 min, and 24 h following patiromer administration.
Following pre-treatment with patiromer, the potassium concentration of both formulas decreased. This effect was mild with the lowest dose but increased in a dose-dependent fashion. Treating for 60 min or 24 h did not yield substantially greater effects than treating for 30 min. Calcium levels increased in both formula groups, mostly in a dose-dependent fashion. Changes in magnesium, sodium, and phosphorus were also seen after patiromer pre-treatment.
Pre-treatment with patiromer decreases the potassium concentration of infant formula. Calcium levels increased after treatment as expected with the majority of ion exchange occurring in 30 min. Treatment of formula with patiromer shows promise as a unique option for managing hyperkalemia.
KeywordsPatiromer Potassium Hyperkalemia Formula
This study was funded in full by the Department of Pediatrics at the University of Wisconsin School of Medicine and Public Health.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Group KW (2009) KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. Executive summary. Am J Kidney Dis 53:S11–S104Google Scholar
- 9.Wood EG, Bunchman TE, Khurana R, Fleming SS, Lynch RE (1990) Complications of nasogastric and gastrostomy tube feedings in children with end stage renal disease. Adv Perit Dial 6:262–264Google Scholar
- 14.Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, Investigators P-H (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32:820–828CrossRefGoogle Scholar
- 15.Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, Investigators A-D (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 314:151–161CrossRefGoogle Scholar
- 19.Russo D, Corrao S, Battaglia Y, Andreucci M, Caiazza A, Carlomagno A, Lamberti M, Pezone N, Pota A, Russo L, Sacco M, Scognamiglio B (2011) Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int 80:112–118CrossRefGoogle Scholar
- 20.Dalgleish DG, Law AJR (1989) pH-Induced dissociation of bovine casein micelles. II. Mineral solubilization and its relation to casein release. J Dairy Res 56:727–735Google Scholar